Drugs / Hiltonol
Hiltonol
also known as
Poly-ICLC · polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose · Hiltonol (Poly-ICLC) · polyinosinic-polycytidylic acid · Hiltinol · HiltonolTM · ICLC · oncovir · +5 more
Other / unclassified targets TLR3 via activation
Trials 65 · started per year
today
1
1
3
2
2
4
5
3
5
2
5
5
2
5
5
4
2
3
1
3
2
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT06472661 | Sep 2024 → Aug 2026 overdue | melanoma | University of Virginia | Recruiting | No outcome recorded |
| Phase 0 | NCT00986609 | Aug 2009 → Aug 2013 | inflammatory breast carcinoma, triple-negative breast carcinoma | Joseph Baar, MD, PhD | Completed | No outcome recorded |
| Phase 0 | NCT00795457 | Jan 2009 → Feb 2013 | low-grade astrocytoma, oligoastrocytoma | Ian F. Pollack, M.D. | Completed | No outcome recorded |
| Phase 133 trials | ||||||
| Phase 1 | NCT06564623 | May 2025 → Mar 2029 expected | biliary tract cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1 | NCT06218303 | Feb 2024 → Aug 2026 overdue | ductal breast carcinoma in situ | Finn, Olivera, PhD | Recruiting | No outcome recorded |
| Phase 1 | NCT05281926 | Oct 2021 → Jun 2024 | hepatocellular carcinoma | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT04672291 | Jul 2021 → Apr 2023 | COVID-19 | Oncovir, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04842682 | Mar 2021 → Nov 2024 | — | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 1 | NCT04024878 | Nov 2020 → Apr 2025 overdue | ovarian cancer | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04525859 | Aug 2020 → Jun 2025 | malignant pleural mesothelioma | Oncovir, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04116320 | Nov 2019 → Aug 2023 | breast cancer, cervical cancer, cutaneous neuroendocrine carcinoma, esophageal cancer +8 | Craig L Slingluff, Jr | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03835533 | Jun 2019 → Oct 2022 | prostate carcinoma | Parker Institute for Cancer Immunotherapy | Completed | No outcome recorded |
| Phase 1 | NCT02950766 | Mar 2019 → Dec 2027 expected | kidney cancer | Patrick Ott, MD, PhD | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03358719 | Mar 2018 → Feb 2020 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT03223103 | Mar 2018 → May 2029 expected | glioblastoma | Adilia Hormigo | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03262103 | Jun 2017 → May 2022 | prostate cancer | Ashutosh Kumar Tewari | Completed | No outcome recorded |
| Phase 1 | NCT03162562 | May 2017 → Nov 2020 | ovarian carcinoma, uterine adnexa cancer | CanariaBio Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02924038 | Apr 2017 → Dec 2022 | astrocytic tumor, oligoastrocytoma, oligodendroglioma | Nicholas Butowski | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02886065 | Mar 2017 → Feb 2027 expected | smoldering plasma cell myeloma | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02549833 | Oct 2016 → Aug 2022 | astrocytic tumor, oligoastrocytoma, oligodendroglioma | Jennie Taylor | Completed | No outcome recorded |
| Phase 1 | NCT02510950 | Dec 2015 → Feb 2017 | glioblastoma | Washington University School of Medicine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01970358 | Apr 2014 → Sep 2015 | melanoma | Patrick Ott, MD, PhD | Completed | No outcome recorded |
| Phase 1 | NCT02061449 | Mar 2014 → Nov 2018 | primary cutaneous T-cell lymphoma | NYU Langone Health | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01783431 | Oct 2012 → Jul 2013 | melanoma | Medical University of South Carolina | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01585350 | Oct 2012 → Jul 2014 | melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Phase 1 | NCT01677962 | Aug 2012 → Sep 2014 | pancreatic adenocarcinoma | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 1 | NCT01532960 | Jul 2012 → Sep 2015 | breast cancer | Craig L Slingluff, Jr | Terminated | No outcome recorded |
| Phase 1 | NCT01842139 | Dec 2011 → Feb 2015 | acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with t(8;21)(q22;q22) translocation, acute myeloid leukemia, del(5q31-q32), acute myeloid leukemia, inv(16)(p13.1;q22) +2 | University of Chicago | Completed | No outcome recorded |
| Phase 1 | NCT01410968 | Aug 2011 → Nov 2013 | malignant pancreatic neoplasm | Carolyn Britten | Completed | No outcome recorded |
| Phase 1 | NCT01299662 | Jun → Sep 2011 | — | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT01127464 | May 2010 → Nov 2012 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT00880867 | Apr 2009 → May 2010 | T-cell and NK-cell neoplasm, neoplasm of mature B-cells | Nevada Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00646152 | Mar 2008 → Dec 2009 | Ebola hemorrhagic fever, acute respiratory distress syndrome, influenza, smallpox | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00616941 | Mar 2008 → Jun 2011 | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1 | NCT00493545 | May 2007 → Jun 2008 | cervical intraepithelial neoplasia | Nventa Biopharmaceuticals Corporation | Unknown | No outcome recorded |
| Phase 1 | NCT00374049 | Jun 2006 → Jan 2008 | prostate cancer | Olivera Finn | Completed | No outcome recorded |
| Phase 1/218 trials · 1 missed | ||||||
| Phase 1/2 | NCT07113106 | Jun 2025 → Oct 2026 expected | — | ANRS, Emerging Infectious Diseases | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06064279 | Jun 2024 | non-small cell lung carcinoma | VA Office of Research and Development | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT03789097 | Apr 2019 → Dec 2023 | breast cancer, head and neck squamous cell carcinoma, non-Hodgkin lymphoma | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 1/2 | NCT03617328 | Nov 2018 → Jan 2024 | melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Phase 1/2 | NCT03721679 | Sep 2018 → Jan 2021 | — | Oncovir, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT02834052 | Jan 2018 → Jul 2022 | metastasis from malignant tumor of colon | Asha Nayak | Completed | No outcome recorded |
| Phase 1/2 | NCT03206047 | Nov 2017 → Nov 2020 | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT02643303 | Dec 2016 → Feb 2022 | breast cancer, cutaneous neuroendocrine carcinoma, head and neck squamous cell carcinoma, kidney cancer +6 | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1/2 | NCT02425306 | May 2015 → Aug 2017 | melanoma | Craig L Slingluff, Jr | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT02413827 | Apr 2015 → Nov 2016 | metastatic melanoma | Celldex Therapeutics | Terminated | No outcome recorded |
| Phase 1/2 | NCT02166905 | Oct 2014 → Aug 2020 | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | Roswell Park Cancer Institute | Completed | Missed primary |
| Phase 1/2 | NCT02071095 | Apr 2014 → Jul 2016 | — | Nina Bhardwaj | Completed | No outcome recorded |
| Phase 1/2 | NCT01976585 | Jan 2014 → Nov 2020 | indolent B-cell non-Hodgkin lymphoma | Joshua Brody | Completed | No outcome recorded |
| Phase 1/2 | NCT01920191 | Aug 2013 → Mar 2016 | glioma | University Hospital, Geneva | Completed | No outcome recorded |
| Phase 1/2 | NCT01079741 | Sep 2010 → Mar 2013 | melanoma | Nina Bhardwaj | Completed | No outcome recorded |
| Phase 1/2 | NCT00948961 | Sep 2009 → Jun 2012 | cancer | Celldex Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT00553683 | Oct 2007 → Feb 2014 | breast cancer, colorectal cancer, cutaneous melanoma, gastric cancer +4 | Rutgers, The State University of New Jersey | Unknown | No outcome recorded |
| Phase 1/2 | NCT00766753 | Dec 2006 → Sep 2009 | malignant glioma | Frank Lieberman | Completed | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT04544007 | Feb 2022 → Jan 2024 | low grade glioma, neurofibromatosis type 1 | University of Alabama at Birmingham | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02423863 | Mar 2015 → Aug 2020 | head and neck cancer, melanoma, sarcoma, skin cancer | Oncovir, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02358187 | Jan 2015 → Jan 2027 expected | low grade glioma | James Felker | Recruiting | No outcome recorded |
| Phase 2 | NCT01984892 | Nov 2013 → Aug 2014 | breast cancer, head and neck squamous cell carcinoma, melanoma, skin basal cell carcinoma +2 | Nina Bhardwaj | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01734564 | Nov 2012 → Dec 2016 | neoplasm | Clinica Universidad de Navarra, Universidad de Navarra | Completed | No outcome recorded |
| Phase 2 | NCT01204684 | Oct 2010 → Aug 2024 | anaplastic astrocytoma, anaplastic oligoastrocytoma, glioblastoma | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01188096 | Aug 2010 → Jul 2019 | brain cancer | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01094496 | Apr 2010 → Jul 2011 | urinary bladder cancer | Celldex Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00262730 | Jan 2006 → Aug 2009 | glioblastoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT00058123 | Mar 2003 → Oct 2007 | central nervous system neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT00052715 | Oct 2002 → Feb 2006 | central nervous system neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Comparator or background therapy61 trials | ||||||
| Phase 0 | NCT07605520 Background | May 2026 → May 2028 expected | — | ANRS, Emerging Infectious Diseases | Recruiting | No outcome recorded |
| Phase 0 | NCT07077616 Background | Jul 2025 → Dec 2027 expected | glioma | Biogenea Pharmaceuticals Ltd. | Recruiting | No outcome recorded |
| Phase 0 | NCT00874861 Background | Apr 2009 → May 2012 | astrocytoma (excluding glioblastoma), oligoastrocytoma, oligodendroglioma | Ian F. Pollack, M.D. | Completed | No outcome recorded |
| Phase 1 | NCT07300475 Background | Oct 2026 → Jul 2030 expected | triple-negative breast carcinoma | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07430202 Background | Oct 2026 → Oct 2030 expected | fibrolamellar hepatocellular carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1 | NCT06665646 Background | Sep 2025 → Nov 2027 expected | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 1 | NCT06411691 Background | Jun 2025 → Mar 2028 expected | colorectal cancer, malignant pancreatic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1 | NCT06529822 Background | Mar 2025 → Jan 2030 expected | gastroesophageal adenocarcinoma, melanoma, non-small cell lung carcinoma, urinary bladder carcinoma | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT05457959 Background | Dec 2024 → Dec 2029 | diffuse glioma, H3 G34 mutant | Jonsson Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT06342908 Background | Jun 2024 → Mar 2027 expected | diffuse glioma, H3 G34 mutant | Jonsson Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05283109 Background | Aug 2023 → Apr 2025 overdue | malignant glioma | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04799431 Background | May 2023 | colorectal cancer, pancreatic ductal adenocarcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Withdrawn | No outcome recorded |
| Phase 1 | NCT05025488 Background | Apr 2023 → Mar 2027 expected | essential thrombocythemia, myelofibrosis | Marina Kremyanskaya | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04616248 Background | Jan 2023 → Jan 2027 expected | basal cell carcinoma, bone sarcoma, breast carcinoma, cutaneous neuroendocrine carcinoma +3 | University of Southern California | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05111353 Background | Dec 2022 → Nov 2025 | malignant pancreatic neoplasm | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT05254184 Background | Nov 2022 → Apr 2027 expected | non-small cell lung carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1 | NCT05098210 Background | Jun 2022 → Nov 2027 expected | acral lentiginous melanoma, female breast carcinoma, hormone receptor-positive breast cancer, malignant conjunctival melanoma +3 | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05013216 Background | Apr 2022 → Oct 2027 expected | hereditary neoplastic syndrome, malignant pancreatic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05010200 Background | Jan 2022 → Jan 2027 expected | prostate cancer | Ashutosh Kumar Tewari | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03068832 Background | Sep 2021 → Mar 2023 | brain cancer | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT04749641 Background | Mar 2021 → Oct 2024 | diffuse intrinsic pontine glioma | Yang Zhang | Completed | No outcome recorded |
| Phase 1 | NCT04117087 Background | May 2020 → Jun 2027 expected | colorectal cancer, malignant pancreatic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04248569 Background | Apr 2020 → Mar 2029 expected | fibrolamellar hepatocellular carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1 | NCT03956056 Background | Feb 2020 → Jul 2022 | malignant pancreatic neoplasm | Washington University School of Medicine | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04201873 Background | Jan 2020 → Aug 2026 | glioblastoma | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT03359239 Background | May 2019 → Oct 2021 | urothelial carcinoma | Matthew Galsky | Completed | Met primary |
| Phase 1 | NCT03166254 Background | Apr 2019 → Jun 2022 | non-small cell lung carcinoma, small cell lung carcinoma | Washington University School of Medicine | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT03422094 Background | Oct 2018 → Apr 2020 | glioblastoma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1 | NCT03121677 Background | Oct 2018 → Sep 2020 | follicular lymphoma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1 | NCT03558945 Background | Jul 2018 → Nov 2023 | pancreatic neoplasm | Anda Biopharmaceutical Development (Shenzhen) Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02947854 Background | Sep 2016 → Mar 2018 | — | PCI Biotech AS | Completed | No outcome recorded |
| Phase 1 | NCT02826434 Background | Aug 2016 → Dec 2026 expected | breast cancer | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02721043 Background | Apr 2016 → Nov 2019 | cancer | Nina Bhardwaj | Completed | No outcome recorded |
| Phase 1 | NCT02427581 Background | Sep 2015 → Dec 2025 | triple-negative breast carcinoma | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT02287428 Background | Nov 2014 → Feb 2027 expected | glioblastoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02149225 Background | Oct 2014 → Jun 2018 | glioblastoma | Immatics Biotechnologies GmbH | Completed | No outcome recorded |
| Phase 1 | NCT01810016 Background | Jan 2014 → May 2016 | metastatic melanoma | Ludwig Institute for Cancer Research | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01834248 Background | Jul 2013 → Jun 2015 | acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent, chronic myelomonocytic leukemia, refractory anemia with excess blasts in transformation | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT01241162 Background | Aug 2010 → Oct 2016 | Ewing sarcoma, neuroblastoma, osteosarcoma, rhabdomyosarcoma +1 | University of Louisville | Completed | No outcome recorded |
| Phase 1 | NCT01012700 Comparator | Nov 2009 → Apr 2010 | — | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT01130077 Background | Feb 2009 → Nov 2024 | childhood brain stem glioma, childhood low-grade glioma, pediatric high-grade glioma | James Felker | Completed | No outcome recorded |
| Phase 1/2 | NCT06782932 Background | May 2025 → Dec 2028 expected | pancreatic adenocarcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06614140 Background | Nov 2022 → Aug 2025 | cancer | Seqker Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04364230 Background | Sep 2020 → Mar 2024 | uveal melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Phase 1/2 | NCT03665545 Background | Oct 2018 → Dec 2023 | adult glioblastoma, brain glioblastoma | University Hospital, Geneva | Completed | No outcome recorded |
| Phase 1/2 | NCT02661100 Background | Jan 2017 → Jul 2018 | melanoma, mesothelioma, non-small cell lung carcinoma, small cell lung carcinoma +2 | Case Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02960230 Background | Nov 2016 → Dec 2023 | diffuse midline glioma, H3 K27M-mutant | Sabine Mueller, MD, PhD | Completed | No outcome recorded |
| Phase 1/2 | NCT02332889 Background | Apr 2015 → Jul 2016 | glioma, medulloblastoma, primitive neuroectodermal tumor | University of Louisville | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT02078648 Background | May 2014 → Sep 2017 | adult glioblastoma | Stemline Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01720836 Background | Nov 2012 → Oct 2027 expected | non-small cell lung carcinoma | Olivera Finn | Recruiting | No outcome recorded |
| Phase 2 | NCT06343077 Comparator | Jan 2024 → Dec 2026 expected | — | Ashutosh Kumar Tewari | Recruiting | No outcome recorded |
| Phase 2 | NCT03606967 Background | Apr 2021 → Dec 2026 expected | invasive breast carcinoma, triple-negative breast carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT02873819 Background | Mar 2017 → May 2021 | oral cavity squamous cell carcinoma | Gliknik Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02754362 Background | Nov 2016 → Jun 2019 | glioblastoma | NYU Langone Health | Withdrawn | No outcome recorded |
| Phase 2 | NCT02334735 Background | Jul 2015 → Jul 2020 | melanoma | Nina Bhardwaj | Completed | No outcome recorded |
| Phase 2 | NCT02129075 Background | Apr 2014 → Mar 2016 | cutaneous melanoma, mucosal melanoma, ocular melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01437605 Comparator | Oct 2011 → Jul 2018 | melanoma | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT01245673 Background | May 2011 → Dec 2015 | plasma cell myeloma | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT00773097 Background | Oct 2008 → Oct 2011 | — | Robert Schoen | Completed | No outcome recorded |
| — | NCT05557240 Background | Sep 2022 → Feb 2024 | malignant glioma | Shanghai 10th People's Hospital | Unknown | No outcome recorded |
| — | NCT00694551 Background | Dec 2008 → Feb 2013 | prostate cancer | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2012-12-20 | Gliknik Inc. | Results Gliknik Announces Interim Clinical Data From Use of Its Immunomodulator Drug Candidate in Multiple Myeloma Patients gliknik.com ↗
Based on the interim analysis, researchers saw a 180-day rate of complete or partial response of 96 percent. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2012-12-20 | Gliknik Inc. | Gliknik Announces Interim Clinical Data From Use of Its Immunomodulator Drug Candidate in Multiple Myeloma Patients gliknik.com ↗ |
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 135 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hiltonol | “The purpose of this study is to test an approach of stimulating the body's immune system to attack prostate cancer. This study will test injection of a substance polylysine and...” NCT03262103 ↗32“In a recently concluded phase 1 study of CDX-1401 in combination with adjuvant Toll-like receptor agonists with Resiquimod (TLR7/8 agonist) and Hiltonol (poly-ICLC; TLR3...” NCT02661100 ↗ “Study of the Immunogenicity of the MUC1 Peptide - Poly-ICLC (Polyinosinic-polycytidylic Acid Stabilized With Polylysine and Carboxymethylcellulose) OR HILTONOL™ Adjuvant...” NCT01720836 ↗ “inject a body defense activator, polyinosinic-polycytidylic acid polylysine carboxymethylcellulose (poly ICLC, hiltonol, oncovir), into and around the cancer to activate...” NCT00553683 ↗ “CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24” NCT04842682 ↗ “Poly-ICLC adjuvant (Hiltonol) used at a dose of 1.0 mg and will be mixed with CD40.RBDv vaccine just prior to subcutaneous injection at day 0.” NCT07605520 ↗ “Poly-ICLC (Polyinosinic-Polycytidylic acid stabilized with polylysine and carboxymethylcellulose, also known as Hiltonol®)” NCT03721679 ↗ “The potential protection of poly-ICLC (Hiltonol®) a double stranded RNA (dsRNA) against EBOV infection was assessed” PMID 30611774 ↗ Jan 2019 “The study is investigating a medication called Poly-ICLC (Hiltonol®, Oncovir), which is an adjuvant.” NCT02071095 ↗ “In the proposed clinical trial we will use poly ICLC (Hiltonol) from Oncovir, Inc as the adjuvant.” NCT01127464 ↗ “Poly-ICLC (also called Hiltonol) is an experimental "viral mimic" and an activator of immunity.” NCT02950766 ↗ |
| Known as | Hiltinol | “an experimental drug called polyICLC (polyinosinic-polycytidylic acid that is stabilized with carboxymethylcellulose and polylysine), also known as Hiltinol, that activates the...” NCT06472661 ↗ |
| Known as | Hiltonol (Poly-ICLC) | “Hiltonol® (Poly-ICLC)” NCT07430202 ↗5“Hiltonol® (Poly-ICLC)” NCT04799431 ↗ “Hiltonol® (Poly-ICLC)” NCT06411691 ↗ “Hiltonol® (Poly-ICLC)” NCT04117087 ↗ “Hiltonol® (Poly-ICLC)” NCT04248569 ↗ “Hiltonol® (Poly-ICLC)” NCT05013216 ↗ |
| Known as | HiltonolTM | “also known as HiltonolTM” NCT00374049 ↗ |
| Known as | ICLC | “The adjuvant poly-interstitial Cajal-like cell (ICLC; Hiltonol) will be injected immediately after and adjacent to DC vaccine site” NCT02332889 ↗ |
| Known as | oncovir | “inject a body defense activator, polyinosinic-polycytidylic acid polylysine carboxymethylcellulose (poly ICLC, hiltonol, oncovir), into and around the cancer to activate...” NCT00553683 ↗ |
| Known as | Poly ICLC: carboxymethylcellulose, polyinosinic-polycytidylic acid & poly-L-lysine double-stranded RNA | “Poly ICLC: carboxymethylcellulose, polyinosinic-polycytidylic acid & poly-L-lysine double-stranded RNA” NCT01079741 ↗ |
| Known as | Poly-ICLC | “The purpose of this study is to test an approach of stimulating the body's immune system to attack prostate cancer. This study will test injection of a substance polylysine and...” NCT03262103 ↗125“Using antigens eluted from the surface of glioblastoma samples, we designed a phase I/II study to test safety and immunogenicity of the IMA950 multipeptide vaccine adjuvanted...” PMID 30753611 ↗ Jul 2019 “This phase II study was designed to determine the objective response rate and 6-month progression free survival of adult patients with recurrent supratentorial anaplastic...” PMID 18850068 ↗ Oct 2008 “Study of the Immunogenicity of the MUC1 Peptide - Poly-ICLC (Polyinosinic-polycytidylic Acid Stabilized With Polylysine and Carboxymethylcellulose) OR HILTONOL™ Adjuvant...” NCT01720836 ↗ “The researched vaccine, containing H3.3-K27M-targeting neoantigen peptides and poly ICLC, will be administered through subcutaneous injection into DIPG patients after they...” NCT04749641 ↗ “To determine the most effective combination of autologous tumor lysate-pulsed DC vaccination, with or without the adjuvant toll-like receptor (TLR) agonists poly-ICLC or...” PMID 37790490 ↗ Sep 2023 “NY-ESO-1 recombinant protein (250 µg) was mixed with Poly-ICLC (1 mg) and Montanide ISA-51 VG (1 mL) and administered SC directly following the ipilimumab infusion every 3...” NCT01810016 ↗ “TAMAVAQ Vaccine plus Poly-ICLC, cGAMP, Granulocyte-macrophage colony stimulating factor (GM-CSF), imiquimod, CpG oligodeoxynucleotides, saponins and monophosphoryl lipid A (MPLA)” NCT07077616 ↗ “This is a phase II, prospective, longitudinal, multi-center trial of poly-ICLC (Hiltonol ®) treatment for progressive low-grade gliomas in pediatric patients with NF1.” NCT04544007 ↗ “The primary objective is to evaluate the immunogenicity of a combination of the 100mer MUC1 peptide and adjuvant Poly-ICLC in boosting the immune response to MUC1.” NCT00773097 ↗ “CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24” NCT04842682 ↗ |
| Known as | Poly-ICLC (Hiltonol, Oncovir) | “Poly-ICLC (Hiltonol®, Oncovir)” NCT02071095 ↗ |
| Known as | polyinosinic-polycytidylic acid | “Polyinosinic-Polycytidylic acid stabilized with polylysine and carboxymethylcellulose (Poly-ICLC)” NCT00646152 ↗1“polyinosinic-polycytidylic acid (poly-ICLC) adjuvant” NCT05254184 ↗ |
| Known as | polyinosinic-polycytidylic acid - poly-L-lysine carboxymethylcellulose | “polyinosinic-polycytidylic acid - poly-L-lysine carboxymethylcellulose (poly-ICLC)” NCT00616941 ↗ |
| Known as | polyinosinic-polycytidylic acid polylysine carboxymethylcellulose | “inject a body defense activator, polyinosinic-polycytidylic acid polylysine carboxymethylcellulose (poly ICLC, hiltonol, oncovir), into and around the cancer to activate...” NCT00553683 ↗ |
| Known as | polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose | “This phase II study was designed to determine the objective response rate and 6-month progression free survival of adult patients with recurrent supratentorial anaplastic...” PMID 18850068 ↗ Oct 20086“PURPOSE: This phase II study was designed to determine the overall survival time of adults with supratentorial glioblastoma treated with the immune modulator,...” PMID 18797818 ↗ Sep 2008 “Study of the Immunogenicity of the MUC1 Peptide - Poly-ICLC (Polyinosinic-polycytidylic Acid Stabilized With Polylysine and Carboxymethylcellulose) OR HILTONOL™ Adjuvant...” NCT01720836 ↗ “Polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC) (10-50 mcg/kg, administered intramuscularly one to three times weekly) was...” PMID 8727138 ↗ Jun 1996 “Poly-ICLC (Polyinosinic-Polycytidylic acid stabilized with polylysine and carboxymethylcellulose, also known as Hiltonol®)” NCT03721679 ↗ “Poly-ICLC (Polyinosinic-polycytidylic Acid Stabilized With Polylysine and Carboxymethylcellulose) or HiltonolTM” NCT00374049 ↗ “SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)” NCT02078648 ↗ |
| Known as | polyinosinic-polycytidylic acid-poly-I-lysine carboxymethylcellulose | “polyinosinic-polycytidylic acid-poly-I-lysine carboxymethylcellulose (poly-ICLC)” PMID 32817593 ↗ Dec 2020 |
| Action | Activate | “to activate sentinel dendritic cells” NCT00553683 ↗ |
| Modality | Other / unclassified | “the immunoadjuvants Montanide and polyinosinic-polycytidylic acid - poly-L-lysine carboxymethylcellulose (poly-ICLC)” NCT00616941 ↗ |
| Route | Intramuscular | “patients receive poly ICLC intramuscularly 3 times weekly” NCT00052715 ↗ |
| Target | TLR3 | “TLR3 agonist Poly-ICLC” NCT01079741 ↗ |